依达拉奉对急性脑梗死患者^1H MRS的影响

The Influence of Edaravone on ^1H MRS in Patients with Acute Cerebral Infarction

目的观察依达拉奉对急性脑梗死患者磁共振氢质子波谱(1H magnetic resonance spectroscopy,1H MRS)的影响,评价依达拉奉治疗急性脑梗死的疗效。方法选择发病24h内的急性脑梗死患者66例,随机分为依达拉奉组(35例)及对照组(31例)。对2组治疗前及4周后美国国立卫生研究院脑卒中量表评分(NIHSS评分)、N-乙酰天冬氨酸(NAA),N-乙酰天冬氨酸与肌酸(Cr)比值(NAA/Cr)进行比较。结果4周后依达拉奉组NIHSS评分(5.71±1.74)较对照组(7.26±2.87)降低明显,差异有统计学意义(P<0.05)。4周后NAA、NAA/Cr值对照组(514±118、1.67±0.23)和依达拉奉组(613±169、1.82±0.28)均较治疗前(对照组345±108、1.34±0.18;治疗组336±115、1.32±0.19)升高,但依达拉奉组升高明显,差异有统计学意义(P<0.05)。结论依达拉奉是一种有效的治疗急性脑梗死的神经保护剂。

Objective To investigate the influence of edaravone on ^1H magnetic resonance spectroscopy（^1H MRS）, study the efficacy of edaravone in treating patients with acute cerebral infarction. Methods 66 patients who had onset of acute cerebral infarction within 24 hours were allocated to edaravone group（ n = 35 ） or the control group （n = 31 ） randomly. National institute of health stroke scale （NIHSS） and N-acetylaspartate （NAA） and N-acetylaspartate/creatine （NAA/Cr） ratio were compared between two groups. Results There were significant differences（P 〈 0.05） in NIHSS between edaravone group （5.71 ± 1.74） and the control group（7.26 ± 2.87） after 4 weeks. The improvement in edaravone group was more significant than that of the control group. NAA, NAA/Cr were higher in edaravone group （613 ± 169,1.82 ± 0.28 ）than that of the control group （514 ± 118,1.67 ± 0.23 ）, The differences were significant （ P 〈 0.05 ）. Conclusions Edaravone is an effective neuroprotective agent in treating acute cerebral infarction.